Clinical Trials

ALK-001 for the treatment of Stargardt Disease ("TEASE" trials)

Active, Recruiting

The purpose of the TEASE study is to determine the long term safety, tolerability and effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.

Learn more about TEASE on clinicaltrials.gov >

ALK-001 for the treatment of Geographic Atrophy ("SAGA" trial)

Active, Not Recruiting

The purpose of the SAGA study is to evaluate the safety and efficacy of ALK-001 in Geographic Atrophy secondary to dry age-related macular degeneration.

Learn more about SAGA on clinicaltrials.gov >